420 THERAPEUTICS
DEAD

Serial Number

87526706

Owner

Canntab Therapeutics Limited

Attorney

Avrom Warren Brown

Filing Date

Jul 13, 2017

Add to watchlist:

No watchlists yet
View on USPTO

420 THERAPEUTICS Trademark

Serial Number: 87526706

420 THERAPEUTICS is a trademark filed by Canntab Therapeutics Limited on July 13, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Canntab Therapeutics Limited

Suite 801
Toronto, Ontario M5C2V9 , CA

Entity Type: 16

Trademark Details

Filing Date

July 13, 2017

Registration Date

Not Registered

Goods & Services

Nutraceuticals for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis;pharmaceuticals and nutraceuticals containing cannabis, cannabinoids or cannabis compounds for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; prescription synthetic narcotics for medical use; pharmaceutical preparations for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; pharmaceutical preparations containing one or more cannabinoids as the active ingredient for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; medicines containing a tetrahydrocannabinol extract for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis;medicines derived from cannabis for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Aug 28, 2018 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 28, 2018 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 30, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jan 30, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jan 30, 2018 CNRT
REMOVED FROM TEAS PLUS
Jan 30, 2018 RFTP
ASSIGNED TO EXAMINER
Jan 23, 2018 DOCK
ASSIGNED TO EXAMINER
Aug 1, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 20, 2017 NWOS
NEW APPLICATION ENTERED
Jul 17, 2017 NWAP